share_log

Canopy Growth | 10-Q: Q1 2025 Earnings Report

Canopy Growth | 10-Q: Q1 2025 Earnings Report

Canopy Growth | 10-Q：2025财年一季报
美股SEC公告 ·  2024/08/09 18:32

Moomoo AI 已提取核心信息

Canopy Growth Corporation reported Q1 fiscal 2025 financial results with net revenue declining 13% year-over-year to $66.2 million, while gross margin improved to 35% from 18%. The company recorded a net loss from continuing operations of $129.2 million, compared to a $10.6 million loss in Q1 fiscal 2024. The increased loss was primarily driven by non-cash fair value changes in financial instruments.The Canada cannabis segment revenue decreased 6% to $37.7 million, with adult-use cannabis down 22% to $18.9 million due to supply constraints and price competition. However, medical cannabis revenue grew 20% to $18.8 million. International markets cannabis revenue remained stable at $10.1 million, while Storz & Bickel revenue increased 2% to $18.5 million.The company strengthened its balance sheet through several initiatives including exchanging $81.2 million of promissory notes into exchangeable shares, raising $68.3 million through a convertible debenture offering, and establishing a $250 million ATM program. Canopy Growth also completed the deconsolidation of Canopy USA as of April 30, 2024 and extended its credit facility maturity to December 2026.
Canopy Growth Corporation reported Q1 fiscal 2025 financial results with net revenue declining 13% year-over-year to $66.2 million, while gross margin improved to 35% from 18%. The company recorded a net loss from continuing operations of $129.2 million, compared to a $10.6 million loss in Q1 fiscal 2024. The increased loss was primarily driven by non-cash fair value changes in financial instruments.The Canada cannabis segment revenue decreased 6% to $37.7 million, with adult-use cannabis down 22% to $18.9 million due to supply constraints and price competition. However, medical cannabis revenue grew 20% to $18.8 million. International markets cannabis revenue remained stable at $10.1 million, while Storz & Bickel revenue increased 2% to $18.5 million.The company strengthened its balance sheet through several initiatives including exchanging $81.2 million of promissory notes into exchangeable shares, raising $68.3 million through a convertible debenture offering, and establishing a $250 million ATM program. Canopy Growth also completed the deconsolidation of Canopy USA as of April 30, 2024 and extended its credit facility maturity to December 2026.
Canopy Growth公司报告了2025财年第一季度的财务结果，净营业收入同比下降13%，降至6620万，而毛利率从18%提高到35%。公司记录的持续运营净亏损为12920万，而2024财年第一季度的亏损为1060万。这一亏损的增加主要是由于金融工具公允价值的非现金变动所致。加拿大大麻业务的营业收入下降6%，降至3770万，成人用大麻下降22%，降至1890万，主要由于供应限制和价格竞争。然而，医疗大麻的营业收入增长了20%，达到1880万。国际市场的大麻收入保持稳定，达到了1010万，而Storz & Bickel的营业收入增长了2%，达到1850万。公司通过多项举措增强了其资产负债表，包括将8120万的票据转换为可交换股票，通过可转换债券发行筹集6830万，以及建立25000万的ATm项目。Canopy Growth还在2024年4月30日完成了Canopy USA的去整合，并将信用设施的到期日延长至2026年12月。
Canopy Growth公司报告了2025财年第一季度的财务结果，净营业收入同比下降13%，降至6620万，而毛利率从18%提高到35%。公司记录的持续运营净亏损为12920万，而2024财年第一季度的亏损为1060万。这一亏损的增加主要是由于金融工具公允价值的非现金变动所致。加拿大大麻业务的营业收入下降6%，降至3770万，成人用大麻下降22%，降至1890万，主要由于供应限制和价格竞争。然而，医疗大麻的营业收入增长了20%，达到1880万。国际市场的大麻收入保持稳定，达到了1010万，而Storz & Bickel的营业收入增长了2%，达到1850万。公司通过多项举措增强了其资产负债表，包括将8120万的票据转换为可交换股票，通过可转换债券发行筹集6830万，以及建立25000万的ATm项目。Canopy Growth还在2024年4月30日完成了Canopy USA的去整合，并将信用设施的到期日延长至2026年12月。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Petros Pharmaceuticals
    PTPI
    -- 0.2930
    坎伯兰药业
    CPIX
    -- 5.150
    OptiNose
    OPTN
    -- 6.000
    Talphera
    TLPH
    -- 0.670
    BioAge Labs
    BIOA
    -- 4.790
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。